IN2014MN01756A - - Google Patents

Info

Publication number
IN2014MN01756A
IN2014MN01756A IN1756MUN2014A IN2014MN01756A IN 2014MN01756 A IN2014MN01756 A IN 2014MN01756A IN 1756MUN2014 A IN1756MUN2014 A IN 1756MUN2014A IN 2014MN01756 A IN2014MN01756 A IN 2014MN01756A
Authority
IN
India
Prior art keywords
compounds
disclosed
therapy
thereofs
subtype
Prior art date
Application number
Inventor
Neelima Sinha
Navnath Popat Karche
Anil Kashiram Hajare
Shridhar Keshav Adurkar
Bikramjit Singh Lairikyengbam
Firoj Aftab Raje
Ajay Ramchandra Tilekar
Baban Rupaji Thube
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN1756MUN2014 priority Critical patent/IN2014MN01756A/en
Publication of IN2014MN01756A publication Critical patent/IN2014MN01756A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed is a compound of formula (I) wherein Y Ring D m and R R are as described herein as a modulator of nicotinic acetylcholine receptors particularly the a7 subtype in a subject in need thereof as well as pharmaceutically acceptable salts polymorphs solvates and isomers thereofs for use either alone or in combinations with suitable other medicaments and pharmaceutical compositions containing such compounds. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy particularly in the prophylaxis and therapy of disorders such as Alzheimer s disease mild cognitive impairment senile dementia and the like.
IN1756MUN2014 2012-03-06 2013-02-22 IN2014MN01756A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN1756MUN2014 IN2014MN01756A (en) 2012-03-06 2013-02-22

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN237KO2012 2012-03-06
IN235KO2012 2012-03-06
IN236KO2012 2012-03-06
IN1307KO2012 2012-11-12
IN1756MUN2014 IN2014MN01756A (en) 2012-03-06 2013-02-22
PCT/IB2013/051455 WO2013132380A1 (en) 2012-03-06 2013-02-22 Thiazole derivatives as alpha 7 nachr modulators

Publications (1)

Publication Number Publication Date
IN2014MN01756A true IN2014MN01756A (en) 2015-07-03

Family

ID=54261190

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1756MUN2014 IN2014MN01756A (en) 2012-03-06 2013-02-22

Country Status (8)

Country Link
US (1) US9388196B2 (en)
EP (1) EP2822946A1 (en)
AU (1) AU2013229177B2 (en)
CA (1) CA2866015A1 (en)
IN (1) IN2014MN01756A (en)
NZ (1) NZ629453A (en)
SG (1) SG11201405239WA (en)
WO (1) WO2013132380A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104603118B (en) * 2012-05-31 2017-10-03 菲尼克斯药品股份公司 Carboxamide- or sulfonamide-substituted thiazoles and related derivatives as modulators of the orphan nuclear receptor RORγ
US20150299178A1 (en) * 2012-11-12 2015-10-22 Lupin Limited Thiazole Derivatives as Alpha 7 NACHR Modulators
US9617210B2 (en) 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
TW201446243A (en) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yl)benzenesulfonamide as alpha 7 nAChR modulator
WO2014203150A1 (en) 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
MX395534B (en) * 2014-07-03 2025-03-25 Celgene Quanticel Res Inc LYSINE-SPECIFIC DEMETHYLASE-1 INHIBITORS.
US10183938B2 (en) 2014-12-16 2019-01-22 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
JP2018516973A (en) 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
US10844051B2 (en) 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH Geminal substituted aminobenzisoxazole compounds as agonists of 7-nicotinic acetylcholine receptors
CN108101860B (en) * 2018-02-08 2021-11-23 苏州敬业医药化工有限公司 Preparation method of cis-2, 6-dimethyl morpholine

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953596A (en) 1973-06-14 1976-04-27 Ici United States Inc. 8-Oxa-3-azabicyclo(3.2.1)octane analgesic compositions and method of alleviating pain in animals
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0772606A1 (en) * 1994-07-27 1997-05-14 G.D. SEARLE & CO. Substituted thiazoles for the treatment of inflammation
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
JP4290872B2 (en) 1997-09-12 2009-07-08 メルク フロスト カナダ リミテツド 2,3,5-trisubstituted pyridines as cyclooxygenase-2 inhibitors
TWI262917B (en) 2002-02-01 2006-10-01 Dainippon Sumitomo Pharma Co 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
FR2840303B1 (en) 2002-05-31 2005-07-15 Rhodia Chimie Sa PROCESS FOR ARYLATION OR VINYLATION OR ALKYLATION OF A NUCLEOPHILIC COMPOUND
SE0201938D0 (en) 2002-06-20 2002-06-20 Astrazeneca Ab New process
DE10244810A1 (en) 2002-09-26 2004-04-08 Bayer Ag New morpholine-bridged indazole derivatives
US7129235B2 (en) 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
WO2005092843A1 (en) 2004-03-29 2005-10-06 Neurosearch A/S Novel urea derivatives and their medical use
ITTO20040264A1 (en) 2004-04-28 2004-07-28 Rotta Res Lab Spa NEW PYROLIC DERIVATIVES WITH ANGIOTENSIN-II ANTAGONIST ACTIVITY
EP1790640A4 (en) 2004-09-09 2009-07-29 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivative and use thereof
US20060142349A1 (en) 2004-12-23 2006-06-29 Pfizer Inc Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
EP1866314B1 (en) 2005-02-16 2010-09-15 NeuroSearch A/S Novel diazabicyclic aryl derivatives and their medical use
FR2885616B1 (en) 2005-05-12 2007-06-22 Servier Lab NOVEL PHENYLPYRIDINYLPIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2007019251A2 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
JP5341516B2 (en) 2005-09-13 2013-11-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 2-aniline-4-aryl-substituted thiazole derivatives
EP1984360B1 (en) 2006-02-03 2014-01-15 Eli Lilly & Company Compounds and methods for modulating FX-receptors
DE602007004307D1 (en) 2006-02-16 2010-03-04 Neurosearch As ENANTIOMERINE CHINUCLIDINYLOXY PYRIDAZINE AND THEIR USE AS NICOTIN ACETYLCHOLINE RECEPTOR LIGANDS
JO3019B1 (en) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-Triazoles
AU2007265116A1 (en) 2006-06-27 2008-01-03 Abbott Laboratories Pyrrole derivatives and their methods of use
MX2008016336A (en) 2006-06-27 2009-01-16 Abbott Lab Thiazoline and oxazoline derivatives and their methods of use.
JP2010509216A (en) 2006-11-02 2010-03-25 メルク エンド カムパニー インコーポレーテッド Heterocyclyl-substituted antihypercholesterolemic compounds
US20080287479A1 (en) 2006-12-20 2008-11-20 Pfizer Inc Inhibitors of serine palmitoyltransferase
US8110588B2 (en) 2007-08-08 2012-02-07 Neurosearch A/S 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GB0718735D0 (en) 2007-09-25 2007-11-07 Prolysis Ltd Antibacterial agents
MX2010003155A (en) 2007-10-04 2010-04-01 Hoffmann La Roche Cyclopropyl aryl amide derivatives and uses thereof.
MX2010003156A (en) 2007-10-04 2010-04-01 Hoffmann La Roche Tetrazole-substituted aryl amide derivatives and uses thereof.
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 1,3,5-trisubstitued triazole derivative
MY152486A (en) 2008-03-19 2014-10-15 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 - triazoles as nicotinic acetylcholine receptor modulators
US7786171B2 (en) 2008-04-04 2010-08-31 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
JP2011516598A (en) 2008-04-17 2011-05-26 グラクソ グループ リミテッド Indole as a modulator of nicotinic acetylcholine receptor subtype alpha-71
BRPI0912196A2 (en) 2008-05-09 2015-10-06 Janssen Pharmaceutica Nv trisubstituted pyrazoles as acetylcholine receptor modulators.
WO2010083444A1 (en) 2009-01-15 2010-07-22 Anvyl, Llc Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
WO2010120854A1 (en) 2009-04-15 2010-10-21 Glaxosmithkline Llc Chemical compounds
WO2010130768A1 (en) 2009-05-14 2010-11-18 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators
JO3250B1 (en) 2009-09-22 2018-09-16 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
JO3078B1 (en) 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv Morpholinothiazoles as alpha 7 positive allosteric modulators
AU2012213086B2 (en) 2011-02-03 2016-05-05 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nAChR
KR20140026378A (en) 2011-02-23 2014-03-05 루핀 리미티드 Heteroaryl derivatives as alpha7 nachr modulators
AU2012235779B2 (en) 2011-03-31 2017-03-02 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease
US8946432B2 (en) 2011-07-05 2015-02-03 Lupin Limited Biaryl derivatives as nAChR modulators

Also Published As

Publication number Publication date
WO2013132380A1 (en) 2013-09-12
NZ629453A (en) 2016-04-29
US9388196B2 (en) 2016-07-12
AU2013229177B2 (en) 2017-03-23
EP2822946A1 (en) 2015-01-14
SG11201405239WA (en) 2014-09-26
US20150291617A1 (en) 2015-10-15
CA2866015A1 (en) 2013-09-12
AU2013229177A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
IN2014MN01756A (en)
PH12013501727A1 (en) Heteroaryl derivatives as alpha7 nachr modulators
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
MX344696B (en) Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease.
PH12014502341A1 (en) Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
PH12015500376A1 (en) Novel bicyclic pyridinones
EA201490807A1 (en) NEW SUBSTITUTED IMIDAZOPIRIMIDINES AS GPBAR1 MODULATORS
IN2014MN02106A (en)
MX2009012168A (en) Pyrrolopyridine derivatives and their use as bace inhibitors.
MX2013008431A (en) Mineralocorticoid receptor antagonists.
SI2875011T1 (en) 5-ht3 receptor antagonists
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MY193041A (en) Novel fused imidazobenzothiazole compounds
IN2013DN02555A (en)
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
MY157629A (en) Fused thiazolo and oxazolo pyrimidinones
MX2016010745A (en) Subsituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists.
MX2015007488A (en) Topical ophthalmological pharmaceutical composition containing regorafenib.
MX2018014165A (en) Heterocyclic compounds useful as anti-bacterial agents and method for production.
NZ600536A (en) Bicyclic compounds as alpha4 beta2 nicotinic acetylcholine receptor ligands
MX2014000855A (en) Quinolinyl glucagon receptor modulators.
GEP20156227B (en) Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same
TN2013000345A1 (en) Heteroaryl derivatives as alpha7 nachr modulators